Letter to the Editor
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Feb 27, 2023; 15(2): 318-320
Published online Feb 27, 2023. doi: 10.4254/wjh.v15.i2.318
Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
Rishi Arora, Michelle T Martin, Justin Boike, Sonalie Patel
Rishi Arora, Department of Pharmacy, Northwestern Medicine, Chicago, IL 60611, United States
Michelle T Martin, Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, University of Illinois Hospital and Health Sciences System, Chicago, IL 60612, United States
Justin Boike, Sonalie Patel, Division of Hepatology, Northwestern Medicine, Chicago, IL 60611, United States
Author contributions: Arora R and Patel S led and Martin MT and Boike J assisted with the study concept and design; Arora R and Patel S equally contributed to acquisition of data and analysis and interpretation of data; Arora R led initial drafting of the manuscript, Patel S led final drafting of the manuscript, and Martin MT and Boike J edited the manuscript; All authors reviewed the manuscript for important intellectual content, gave final approval of data, and are accountable for the work.
Conflict-of-interest statement: Martin MT and Patel S serve on the speakers’ bureau for AbbVie and Gilead. Martin MT has received grant funding from Gilead and Merck, served on the advisory board for AbbVie and Gilead, and is a minor shareholder of AbbVie, Gilead, and Merck stock.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sonalie Patel, PharmD, Pharmacist, Division of Hepatology, Northwestern Medicine, 676 N St. Clair 560, Chicago, IL 60611, United States. sonalie.patel@nm.org
Received: December 9, 2022
Peer-review started: December 9, 2022
First decision: December 24, 2022
Revised: December 30, 2022
Accepted: January 17, 2023
Article in press: January 17, 2023
Published online: February 27, 2023
Processing time: 76 Days and 21.8 Hours
Abstract

Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.

Keywords: Hepatitis C virus; Direct-acting antivirals; Liver transplantation; Glecaprevir/pibrentasvir; Sofosbuvir; Ribavirin

Core Tip: In the post-liver transplant population, current national guidance only recommends sofosbuvir/velpatasvir/voxilaprevir, with or without ribavirin, for recurrent hepatitis C virus treatment in direct-acting antiviral-experienced patients. We describe an alternative regimen of glecaprevir/pibrentasvir in combination with sofosbuvir that resulted in sustained virologic response without treatment-related adverse events.